Richard A. Heyman - 17 Feb 2026 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Reporting relationship: Director
Issuer ticker: ELVN
Reported as of: 17 Feb 2026
Net transaction value: -$32,196
SEC form: 4
Accepted by SEC: 19 Feb 2026, 18:38:29 UTC
Prior SEC filing: 17 Feb 2026
Next SEC filing: 08 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Ben Hohl, by power of attorney

Key filing fact

Richard A. Heyman filed Form 4 for Enliven Therapeutics, Inc. (ELVN) on 19 Feb 2026.

Key facts

This page summarizes Richard A. Heyman's Form 4 filing for Enliven Therapeutics, Inc. (ELVN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Feb 2026, 18:38.

Change

Previous filing in this sequence was filed on 17 Feb 2026.
Current net transaction value: -$32,196.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001584759 Primary reporting owner

Heyman Richard A.

Relationship: Director
Address: C/O ENLIVEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER
Signature: /s/ Ben Hohl, by power of attorney
Signature date: 19 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELVN transaction

Common Stock

Sale

Transaction value: $32,196
Shares: -1,230
Change %: -5.2%
Price: $26.18
Shares after: 22,647
Date: 17 Feb 2026
Ownership: See footnote
Footnotes: F1, F2, F3

ELVN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 123,673
Date: 17 Feb 2026
Ownership: Direct

ELVN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 25,545
Date: 17 Feb 2026
Ownership: See footnote
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust").

Footnote F2

This transaction was executed in multiple trades at prices ranging from $25.765 to $26.6949. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F3

The shares are held of record by the Heyman Daigle Trust.

Footnote F4

The shares are held of record by RAHD Capital LLC, for which the Reporting Person serves as a managing member.